|
시장보고서
상품코드
2134015
재조합 인간 신경교세포 성숙 인자 베타 시장 : 유형별, 용도별, 유통별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Recombinant Human Glial Maturation Factor Beta Market, By Type, By Application, By Distribution, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
세계의 재조합 인간 신경교세포 성숙 인자 베타 시장 규모는 2025년에 1억 4,090만 달러로 평가되며, 2026년부터 2033년까지 CAGR 6.5%로 확대될 것으로 전망됩니다.
재조합 인간 신경교세포 성숙 인자 베타(GMFB)는 액틴 리모델링 및 신경, 글리아, 염증, 재생, 질병의 기전을 연구하기 위해 실험실에서 합성된 인간 GMFB에 초점을 맞춘 연구용 단백질입니다. 인간 GMFB는 염색체 14q22.2에 위치한 GMFB 유전자에 의해 암호화되는, 검증된 142개의 아미노산으로 구성된 단백질로, 액틴 필라멘트의 조절에 관여하는 ADF 상동 도메인을 포함하고 있습니다. 이 시장은 더 광범위한 성장 인자 시장과는 차별화됩니다. 그 이유는 GMFB가 주로 특수한 분자 연구용 시약으로 공급되고 있으며, 기존의 치료용이나 임상용 제품으로는 공급되지 않기 때문입니다. 그 결과, 수요는 실험의 재현성, 발현 시스템, 순도, 내독소, 서열 정확성 및 호환성 등의 요인에 따라 좌우됩니다. 2025년에 GMFB 연구가 간 재생, 당뇨병성 망막병증, 대사성 질환으로 확대되고 있다는 사실은, 그 연구적 중요성이 기존의 신경생물학적 응용 분야를 넘어 확장되고 있음을 시사합니다.
재조합 인간 신경교세포 성숙 인자 베타 시장 - 시장 역학
기존 신경생물학을 넘어선 GMFB 연구의 확대
수요를 견인하는 중요한 요인 중 하나는, 기존 신경생물학의 영역을 넘어선 질환 기전에서 GMFB가 실험적으로 수행하는 역할이 부각되고 있다는 점입니다. 2025년에는 동료 심사를 거친 문헌에서 간 재생, 당뇨병성 망막병증, 인슐린 저항성이라는 적어도 3가지의 서로 다른 적응증에 대해 이 단백질이 조사되었으며, 각각 간세포 증식, 리소좀 기능 장애, 지방세포의 지질 대사와 GMFB의 관련성이 밝혀졌습니다. 이러한 다양화로 인해 구매 수요는 단순한 신경생물학용 시약에서 세포, 조직, 질병 모델 실험에 적합한 다목적 단백질로 변화하고 있습니다. 따라서 각 공급업체들은 서열의 정확성, 순도, 발현 플랫폼, 그리고 메커니즘에 기반한 분석의 재현성을 가능하게 하는 문서화를 놓고 경쟁을 벌이고 있습니다. 이것이 의미하는 바는 분명합니다. 즉, GMFB에 대한 생물학적 지식이 확대됨에 따라, 재조합 인간 단백질이 제어된 연구 재료로 활용되는 실험 워크플로우의 수가 증가하고 있다는 것입니다.
재조합 인간 신경교세포 성숙 인자 베타 시장 - 시장 세분화 분석:
세계 재조합 인간 신경교세포 성숙 인자 베타 시장은 유형, 용도, 유통 및 지역을 기준으로 세분화되어 있습니다.
유형별로는 순도가 상업적 지표가 됩니다. 이는 GMFB 실험이, 특히 재조합 물질을 사용한 세포 분석에서 외래 단백질의 존재, 응집, 내독소 및 로트 간 편차에 크게 영향을 받는 경우가 많기 때문입니다. 순도 95% 미만은 단백질이 프로브로 사용되는 탐색적 생화학 연구에 적합하지만, 순도 95% 이상은 기전 규명을 목적으로 하는 세포 기반 연구에 더 적합합니다. 용도의 차이에 따라 공급업체들이 이 두 가지 옵션을 제공하고 있음이 분명합니다. 예를 들어, 2025년 1월 데이터시트에 따르면 Novus Biologicals사는 순도 98% 이상의 재조합 인간 GMF-β 단백질을 제공하는 반면, 다른 공급업체는 순도 95% 이상의 인간 GMFB를 제공하고 있습니다. 따라서 순도는 현재 카탈로그상의 분류라기보다는 실험상의 고려 사항이 되고 있습니다.
용도별로 살펴보면, 연구의 복잡성 정도나 세포 골격, 신경생물학, 염증, 질병 연구에서의 접근 방식의 폭이 넓기 때문에 특정 한 가지 기법이 다른 기법을 압도하기보다는 용도의 다양성이 상업 환경을 지배하고 있습니다. 학술 기관이나 연구 센터는 기전,생물학, 그리고 질환과의 연관성 연구에 적합한 반면, 진단 검사실에서는 바이오마커와 관련된 연구가 수행될 가능성이 있습니다. 또한, 생명공학 기업이나 제약 기업은 GMFB의 치료 가능성을 탐구하는 데 관심을 가질 수도 있습니다. 이 조사 분야의 중요성은 2025년도 NIH(미국 국립보건원) 예산에서도 입증됩니다. 그중 국립신경질환·뇌졸중연구소(NINDS) 예산에서 2025 회계연도 신경과학 대출 상환 프로그램에 63건의 연구비가 배정되었습니다. 따라서 용도의 세부 내역은 각 기업의 환경과 다루는 연구 과제의 차이를 반영한다고 할 수 있습니다.
재조합 인간 신경교세포 성숙 인자 베타(GMFB) 시장 - 지역별 분석
북미는 견고한 생의학 연구 인프라와 공공 자금을 통한 신경과학 연구의 풍부한 축적이 결합되어 계속해서 주요 시장으로 자리 잡고 있습니다. NIH의 2025 회계연도 조사에 따르면, 미국에서는 3만 9,239건의 연구 프로젝트 보조금이 지급되었으며, 연구 프로젝트 보조금은 전체 연구 보조금의 80%를 차지하고 있습니다. 이러한 수치에는 GMFB가 명시적으로 언급되어 있지는 않지만, 연구 활동의 규모를 고려할 때 관련 재조합 단백질이 분자·세포 수준 또는 질환 모델 연구에 활용될 가능성이 시사됩니다. 따라서 GMFB에 있어 북미가 갖는 주요 의의는, 새로운 생물학적 제제를 활용한 실험에 적극적인 연구 기관이 다수 존재한다는 점에 있습니다. 공급업체의 입장에서 볼 때, 이는 엄격한 연구용 등급의 문서화 요건을 충족하고, 로트별 일관된 품질 관리를 수행하며, 확립된 실험용 시약 유통 채널에 대한 접근을 확보하는 것이 성공의 중요한 요인임을 시사합니다.
아시아태평양의 주요 특징은 중국 및 기타 지역 연구 거점에서 GMFB의 유전자 조절을 수반하는 실험적 연구가 점점 증가하고 있다는 점입니다. 2025년, Southern Medical University는 제브라피쉬 모델을 이용한 간세포 특이적 유전자 노크다운 실험에 대한 세부 내용을 담은 프리프린트를 발표하며, GMFB를 간 재생 및 대사성 간 질환의 경로와 연관지었습니다. 기관 차원에서는 South China Normal University가 2025년에 국가자연과학기금(NSFC)의 지원을 받은 128건의 프로젝트를 보고했으며, 그 내역은 일반 프로그램 지원금 58건, 신진 과학자 기금 C류 지원금 57건입니다. 이러한 사례들은 다양한 실험 목적을 위해 특수한 재조합 단백질을 도입할 수 있는 유능한 구매자층이 등장하고 있음을 보여줍니다. 지역적 관점에서 볼 때, 아시아태평양은 새로운 실험 연구 수요를 창출하는 능력이 높아지고 있어 GMFB에게 중요한 시장이 되고 있습니다.
목차
제1장 재조합 인간 신경교세포 성숙 인자 베타 시장 개요
제2장 주요 요약
제3장 재조합 인간 신경교세포 성숙 인자 베타 시장 동향
제4장 재조합 인간 신경교세포 성숙 인자 베타 산업 분석
제5장 재조합 인간 신경교세포 성숙 인자 베타 시장 : 높아지는 지정학적 긴장의 영향
제6장 재조합 인간 신경교세포 성숙 인자 베타 시장 상황
제7장 재조합 인간 신경교세포 성숙 인자 베타 시장 : 유형별
제8장 재조합 인간 신경교세포 성숙 인자 베타 시장 : 용도별
제9장 재조합 인간 신경교세포 성숙 인자 베타 시장 : 유통별
제10장 재조합 인간 신경교세포 성숙 인자 베타 시장 : 지역별
제11장 주요 벤더 분석 : 재조합 인간 신경교세포 성숙 인자 베타 산업
제12장 AnalystView의 전방위 전망
KSM 26.10.02Recombinant Human Glial Maturation Factor Beta Market size was valued at US$ 140.9 Million in 2025, expanding at a CAGR of 6.5% from 2026 to 2033.
Recombinant human glial maturation factor beta (GMFB) is a research use protein market focused on laboratory synthesized human GMFB for studying actin remodeling and neural, glial, inflammatory, regenerative, and disease mechanisms. Human GMFB is a validated 142 amino acid protein encoded by the gene GMFB on chromosome 14q22.2, which contains an ADF homology domain involved in actin filament regulation. The market is distinct from the larger growth factor markets because GMFB is primarily supplied as a specialized molecular research reagent and not as a conventional therapeutic or clinical product. As a result, demand is driven by factors such as experimental reproducibility, expression system, purity, endotoxin, sequence fidelity, and compatibility. The 2025 expansion of GMFB research into liver regeneration, diabetic retinopathy, and metabolic disease suggests that its research relevance is expanding beyond traditional neurobiological applications.
Recombinant Human Glial Maturation Factor Beta Market- Market Dynamics
Expansion of GMFB Research Beyond Conventional Neurobiology
A significant demand driver is the emerging experimental role of GMFB in disease mechanisms beyond its classical neurobiological realm. In 2025, peer-reviewed literature investigated the protein in at least three distinct indications-liver regeneration, diabetic retinopathy, and insulin resistance-linking GMFB to hepatocyte proliferation, lysosomal dysfunction, and adipocyte lipid metabolism, respectively. This diversification transforms the purchasing requirement from a neurobiological reagent into a multi-use protein amenable to cellular, tissue, and disease model experimentation. As such, suppliers compete on sequence fidelity, purity, expression platform, and documentation enabling mechanistic assay reproduction. The implication is specific: expanded GMFB biology increases the number of experimental workflows in which recombinant human protein may serve as a controlled research input.
Recombinant Human Glial Maturation Factor Beta Market- Segmentation Analysis:
The Global Recombinant Human Glial Maturation Factor Beta Market is segmented on the basis of Type, Application, Distribution, and Region.
By type, purity is a commercial indicator because GMFB experiments often depend on the presence of foreign proteins, aggregation, endotoxin, and lot-to-lot variation, especially when dealing with cellular assays of any recombinant material. Purity <95% satisfies exploratory biochemical research, in which the protein is used as a probe, while purity >=95% is more relevant to mechanistic, cell-based studies. It is evident that suppliers offer a choice between the two options due to their different applications. For instance, according to the January 2025 datasheet, Novus Biologicals provides a recombinant human GMF-beta protein with purity >98%, while other suppliers offer human GMFB with purity >=95%. Therefore, purity is now more of an experimental consideration than a catalog classification.
By application, application diversity dominates the commercial environment due to varying levels of research complexity and the range of approaches to the study of the cytoskeleton, neurobiology, inflammation, and disease rather than one specific method dominating the others. Academic institutions and research centers are more suitable for studying mechanisms, biology, and disease relationships, while diagnostic labs may perform studies related to biomarkers; biotech and pharma companies may be interested in exploring the therapeutic potential of GMFB. The research area can be justified by the 2025 NIH budget, of which the National Institute of Neurological Disorders and Stroke's budget is allocated 63 awards in the FY2025 Loan Repayment Program for Neuroscience. Therefore, the application breakdown reflects the differences in the corporate environments and research challenges addressed.
Recombinant Human Glial Maturation Factor Beta Market- Geographical Insights
North America continues to be a major market due to the combined efforts of a robust biomedical research infrastructure and a deep pool of publicly funded neurological studies. According to the NIH's FY2025 survey, there were 39,239 Research Project Grant awards in the U.S., with research project grants accounting for 80% of all research grants. While these figures do not explicitly mention GMFB, the volume of research activity indicates the potential for incorporating relevant recombinant proteins into molecular, cellular, or disease model studies. Thus, North America's primary significance for GMFB lies in the presence of numerous research organizations willing to experiment with novel biologics. For suppliers, this suggests that meeting rigorous research-grade documentation requirements, consistent lot quality control, and access to established laboratory reagent distribution channels are critical success factors.
Asia-Pacific's primary distinction is the growing number of experimental studies conducted within China and other regional research hubs that involve GMFB gene modulation. In 2025, Southern Medical University published a preprint detailing hepatocyte-specific gene knockdown experiments in zebrafish models, linking GMFB to liver regeneration and metabolic liver disease pathways. At the institutional level, South China Normal University reported 128 NSFC-funded projects in 2025, including 58 General Program grants and 57 Young Scientists Fund Class C awards. These examples illustrate the emergence of a qualified buyer base capable of adopting specialized recombinant proteins for various experimental purposes. From a regional perspective, Asia-Pacific is an important market for GMFB due to its rising capacity to generate novel experimental research needs.
Recombinant Human Glial Maturation Factor Beta Market- Competitive Landscape:
Competition is fragmented around technical specifications rather than large-scale product differentiation. Novus Biologicals stresses highly purified E. coli-derived recombinant GMF-beta, while MedChemExpress lists human GMFB products at >=95% purity; OriGene differs by both E. coli and HEK293T expression formats, and Abnova supplies GMFB-related research reagents produced through alternative expression approaches. The competitive field, therefore, spans at least three different expression approaches: bacterial, mammalian, and wheat-germ systems, thus offering buyers options according to experimental requirements. Abcam's GMFB product listing was also updated in August 2025 and provides both 100- and 500-µg formats, thus illustrating continued catalog maintenance. Competitive advantage, therefore, depends upon purity assurance, expression system suitability, formulation, applicability documentation, and reproducibility.
Recent Developments:
In July 2025, a research team from Southern Medical University published a study revealing that hepatocyte GMFB regulates liver regeneration and metabolic liver disease. Three zebrafish groups, including hepatocyte-specific GMFB knockout, GMFB overexpression, and wild-type, were used in the experiment. The experiment involved comparing the liver injury and metabolic disease models.
In August 2025, Tongji University School of Medicine researchers identified that GMFB plays a systemic role in regulating insulin resistance and studied the relationship between GMFB and CARM1 in adipocyte lipid metabolism. The research controlled the biological behaviors of GMFB in rats, mice, and human cells and discovered DS19, which could be a possible GMFB inhibitor.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RECOMBINANT HUMAN GLIAL MATURATION FACTOR BETA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Thermo Fisher Scientific Inc. (PeproTech)
- Bio-Techne Corporation (R&D Systems)
- Sino Biological Inc.
- Abcam plc
- Novoprotein Scientific Inc.
- ProSpec-Tany TechnoGene Ltd.
- RayBiotech, Inc.
- Creative BioMart
- Cusabio Technology LLC
- BPS Bioscience, Inc.
- Cloud-Clone Corp.
- GenScript Biotech Corporation
- ACROBiosystems
- OriGene Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Elabscience Biotechnology Inc.
- Others
GLOBAL RECOMBINANT HUMAN GLIAL MATURATION FACTOR BETA MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Purity <95%
- Purity >=95%
GLOBAL RECOMBINANT HUMAN GLIAL MATURATION FACTOR BETA MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Academic Institutions
- Research Centers
- Diagnostic Laboratories
- Pharmaceutical & Biotech Companies
- Others
GLOBAL RECOMBINANT HUMAN GLIAL MATURATION FACTOR BETA MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2020 - 2033
- Distributors
- Direct Sales
- Online Sales/E-commerce
GLOBAL RECOMBINANT HUMAN GLIAL MATURATION FACTOR BETA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Recombinant Human Glial Maturation Factor Beta Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.2. Competitive Insights
3. Recombinant Human Glial Maturation Factor Beta Key Market Trends
- 3.1. Recombinant Human Glial Maturation Factor Beta Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Recombinant Human Glial Maturation Factor Beta Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Recombinant Human Glial Maturation Factor Beta Market Opportunities
- 3.4. Recombinant Human Glial Maturation Factor Beta Market Future Trends
4. Recombinant Human Glial Maturation Factor Beta Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Recombinant Human Glial Maturation Factor Beta Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Recombinant Human Glial Maturation Factor Beta Market Landscape
- 6.1. Recombinant Human Glial Maturation Factor Beta Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Recombinant Human Glial Maturation Factor Beta Market - By Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
- 7.1.2. Purity <95%
- 7.1.3. Purity >=95%
8. Recombinant Human Glial Maturation Factor Beta Market - By Application
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
- 8.1.2. Academic Institutions
- 8.1.3. Research Centers
- 8.1.4. Diagnostic Laboratories
- 8.1.5. Pharmaceutical & Biotech Companies
- 8.1.6. Others
9. Recombinant Human Glial Maturation Factor Beta Market - By Distribution
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution, 2025 & 2033 (%)
- 9.1.2. Distributors
- 9.1.3. Direct Sales
- 9.1.4. Online Sales/E-commerce
10. Recombinant Human Glial Maturation Factor Beta Market- By Geography
- 10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 10.2. North America
- 10.2.1. Overview
- 10.2.2. Recombinant Human Glial Maturation Factor Beta Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.2.7. U.S.
- 10.2.7.1. Overview
- 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.7.3. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.2.7.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.2.7.5. U.S. Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.2.8. Canada
- 10.2.8.1. Overview
- 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.8.3. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.2.8.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.2.8.5. Canada Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3. Europe
- 10.3.1. Overview
- 10.3.2. Recombinant Human Glial Maturation Factor Beta Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.7. Germany
- 10.3.7.1. Overview
- 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.7.3. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.7.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.7.5. Germany Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.8. UK
- 10.3.8.1. Overview
- 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.8.3. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.8.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.8.5. UK Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.9. France
- 10.3.9.1. Overview
- 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.9.3. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.9.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.9.5. France Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.10. Italy
- 10.3.10.1. Overview
- 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.10.3. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.10.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.10.5. Italy Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.11. Spain
- 10.3.11.1. Overview
- 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.11.3. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.11.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.11.5. Spain Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.12. The Netherlands
- 10.3.12.1. Overview
- 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.13. Sweden
- 10.3.13.1. Overview
- 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.13.3. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.13.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.13.5. Sweden Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.14. Russia
- 10.3.14.1. Overview
- 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.14.3. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.14.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.14.5. Russia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.15. Poland
- 10.3.15.1. Overview
- 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.15.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.15.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.15.5. Poland Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.16. Denmark
- 10.3.16.1. Overview
- 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.16.3. Denmark Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.16.4. Denmark Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.16.5. Denmark Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.3.17. Rest of Europe
- 10.3.17.1. Overview
- 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Recombinant Human Glial Maturation Factor Beta Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.7. China
- 10.4.7.1. Overview
- 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.7.3. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.7.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.7.5. China Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.8. India
- 10.4.8.1. Overview
- 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.8.3. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.8.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.8.5. India Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.9. Japan
- 10.4.9.1. Overview
- 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.9.3. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.9.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.9.5. Japan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.10. South Korea
- 10.4.10.1. Overview
- 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.10.3. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.10.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.10.5. South Korea Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.11. Australia
- 10.4.11.1. Overview
- 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.11.3. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.11.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.11.5. Australia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.12. Indonesia
- 10.4.12.1. Overview
- 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.12.5. Indonesia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.13. Thailand
- 10.4.13.1. Overview
- 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.13.3. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.13.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.13.5. Thailand Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.14. Philippines
- 10.4.14.1. Overview
- 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.14.3. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.14.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.14.5. Philippines Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.15. Taiwan
- 10.4.15.1. Overview
- 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.15.3. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.15.4. Taiwan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.15.5. Taiwan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.16. Vietnam
- 10.4.16.1. Overview
- 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.16.3. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.16.4. Vietnam Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.16.5. Vietnam Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.4.17. Rest of APAC
- 10.4.17.1. Overview
- 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.17.3. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.17.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.4.17.5. Rest of APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Recombinant Human Glial Maturation Factor Beta Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.5.7. Brazil
- 10.5.7.1. Overview
- 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.7.3. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.7.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.5.7.5. Brazil Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.5.8. Mexico
- 10.5.8.1. Overview
- 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.8.3. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.8.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.5.8.5. Mexico Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.5.9. Argentina
- 10.5.9.1. Overview
- 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.9.3. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.9.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.5.9.5. Argentina Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.5.10. Colombia
- 10.5.10.1. Overview
- 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.10.3. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.10.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.5.10.5. Colombia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.5.11. Rest of LATAM
- 10.5.11.1. Overview
- 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Recombinant Human Glial Maturation Factor Beta Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.7. Saudi Arabia
- 10.6.7.1. Overview
- 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.8. UAE
- 10.6.8.1. Overview
- 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.8.3. UAE Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.8.4. UAE Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.8.5. UAE Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.9. Israel
- 10.6.9.1. Overview
- 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.9.3. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.9.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.9.5. Israel Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.10. Turkey
- 10.6.10.1. Overview
- 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.10.3. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.10.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.10.5. Turkey Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.11. Algeria
- 10.6.11.1. Overview
- 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.11.3. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.11.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.11.5. Algeria Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.12. Egypt
- 10.6.12.1. Overview
- 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.12.3. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.12.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.12.5. Egypt Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.13. Iran
- 10.6.13.1. Overview
- 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.13.3. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.13.4. Iran Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.13.5. Iran Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.14. Qatar
- 10.6.14.1. Overview
- 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.14.3. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.14.4. Qatar Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.14.5. Qatar Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
- 10.6.15. Rest of MEA
- 10.6.15.1. Overview
- 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.15.3. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.15.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 10.6.15.5. Rest of MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Recombinant Human Glial Maturation Factor Beta Industry
- 11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
- 11.2. Company Profiles
- 11.2.1. Thermo Fisher Scientific Inc. (PeproTech)
- 11.2.2. Bio-Techne Corporation (R&D Systems)
- 11.2.3. Sino Biological Inc.
- 11.2.4. Abcam plc
- 11.2.5. Novoprotein Scientific Inc.
- 11.2.6. ProSpec-Tany TechnoGene Ltd.
- 11.2.7. RayBiotech, Inc.
- 11.2.8. Creative BioMart
- 11.2.9. Cusabio Technology LLC
- 11.2.10. BPS Bioscience, Inc.
- 11.2.11. Cloud-Clone Corp.
- 11.2.12. GenScript Biotech Corporation
- 11.2.13. ACROBiosystems
- 11.2.14. OriGene Technologies, Inc.
- 11.2.15. Bio-Rad Laboratories, Inc.
- 11.2.16. Elabscience Biotechnology Inc.
- 11.2.17. Others
12. 360 Degree AnalystView
13. Appendix
- 13.1. Research Methodology
- 13.2. References
- 13.3. Abbreviations
- 13.4. Disclaimer
- 13.5. Contact Us
